# Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world

> **NCT07356960** · — · NOT_YET_RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 103 (estimated)

## Conditions studied

- Acute Lymphobkastic Leukemia
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07356960
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07356960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07356960, "Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07356960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*